Clinical Trials Logo

Clinical Trial Summary

Impedance aggregometry (IA) (Multiplate®)is a new whole blood platelet function test with potential use in anesthesia and intensive care. Most anesthetic drugs have been shown to have in vitro antiplatelet activity. The goal of this in vitro study is to evaluate the effect of several drugs, frequently used in cardiac anesthesia and intensive care, on platelet function as measured by IA


Clinical Trial Description

Impedance aggregometry (IA) on the multiple platelet function analyzer (Multiplate®) ) is a whole blood point of care test evaluating platelet function. In IA, the increase in electrical impedance of whole blood is measured after the addition of a platelet activator. Some of the activators available are arachidonic acid (ASPI Test), ADP (ADP Test), TRAP-6 (TRAP Test) and collagen (COL TEST).

When an activator is added to the blood sample, the activated platelets will aggregate on the electrodes embedded in the test recipient. As platelets accumulate on the electrodes surface, the impedance will increase. The increase is measured and expressed in arbitrary units (AU). Reduced impedance implies platelet dysfunction or the presence of specific platelet inhibitors. For example, the ASPI test is inhibited in the presence of acetylsalicylic Acid and clopidrel inhibits the ADP test. Thrombin (TRAP) is an extremely potent agonist which can be used to monitor GpIIb/IIIa therapy.

The Multiplate® analyzer may have an important role in detecting and analyzing perioperative coagulopathies, but many drugs, routinely used in cardiac anesthesia or in the intensive care unit, have known in vitro antiplatelet effects, and may interfere with IA interpretation.

The goal of the study is to evaluate the influence of lidocaine, propofol, midazolam, and magnesium on the results of impedance aggregometry and to understand to which extent the tests are modified by the presence of one of these drugs.

20 healthy volunteers aged 18 to 65 years old will be recruited. Exclusion criteria are the use of non-steroidal anti-inflammatory drugs for 2 weeks prior to donation and known coagulation disorders. Whole blood is taken from the antecubital vein. Platelet count is measured. Blood samples for Multiplate® analysis are drawn in hirudin anticoagulated tubes. During storage, blood is gently moved in order to avoid sedimentation and spontaneous platelet aggregation.

For each sample baseline measurements are performed using ASPI Test, ADP Test, TRAP Test and COL Test.

The four study drugs are added to the blood samples, in isovolumic dilutions, to obtain subclinical, normal or near toxic plasma concentrations (table 1).

Study drugs low intermediate high Lidocaine (mcg/ml) 1 3 6 Magesium (mMol/l) 0.4 1 2.5 Midazolam (ng/ml) 150 250 500 Propofol (mcg/ml) 2 5 8 Table 1. Plasma concentration of the four study drugs

For every concentration, IA is measured using the 4 different activators. For every test and dose, the area under the curve is compared with the baseline. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01454427
Study type Observational
Source University of Lausanne Hospitals
Contact
Status Completed
Phase N/A
Start date October 2010
Completion date May 2011

See also
  Status Clinical Trial Phase
Completed NCT04554901 - The Effect of Cocoa on Platelet Function Profiles in Patients N/A
Completed NCT03621020 - Clinical Performance Evaluation of T-TAS 01 PL Chip
Completed NCT03667066 - clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad
Recruiting NCT05588011 - Influence of Oxygenator Selection on Platelet Function and Rotational Thromboelastometry Following Cardiopulmonary Bypass N/A
Completed NCT03188705 - CES1 Carriers in the PAPI Study Phase 4
Recruiting NCT03583229 - Coronary Artery Disease After Heart Transplantation N/A
Recruiting NCT05730114 - Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
Completed NCT03182946 - Correcting Platelet Dysfunction After Traumatic Brain Injury
Completed NCT05033236 - Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)
Recruiting NCT04419948 - Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DM N/A
Completed NCT04400760 - The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts. Phase 2/Phase 3
Completed NCT03458351 - RIPC and Platelet Activation on Platelet Activation During Cardiopulmonary Bypass N/A
Completed NCT02368730 - Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures N/A
Not yet recruiting NCT04876573 - Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19 Phase 2
Completed NCT04734028 - PTRG-DES Consortium
Completed NCT01382134 - Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction N/A
Completed NCT03028064 - Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding
Completed NCT05237492 - The Influence of Tramadol on Platelet Function Phase 4
Completed NCT01957345 - Evaluation of a New Approach of the Diagnosis of Constitutional Functional Disorders of Platelets N/A
Completed NCT03049566 - Low-dose Acetylsalicylic Acid Before Non-cardiac Surgery N/A